Stanford Health Policy is a joint effort of the Freeman Spogli Institute for International Studies and the Stanford School of Medicine
FSI’s researchers assess health and medicine through the lenses of economics, nutrition and politics. They’re studying and influencing public health policies of local and national governments and the roles that corporations and nongovernmental organizations play in providing health care around the world. Scholars look at how governance affects citizens’ health, how children’s health care access affects the aging process and how to improve children’s health in Guatemala and rural China. They want to know what it will take for people to cook more safely and breathe more easily in developing countries.
FSI professors investigate how lifestyles affect health. What good does gardening do for older Americans? What are the benefits of eating organic food or growing genetically modified rice in China? They study cost-effectiveness by examining programs like those aimed at preventing the spread of tuberculosis in Russian prisons. Policies that impact obesity and undernutrition are examined; as are the public health implications of limiting salt in processed foods and the role of smoking among men who work in Chinese factories. FSI health research looks at sweeping domestic policies like the Affordable Care Act and the role of foreign aid in affecting the price of HIV drugs in Africa.
Low-molecular-weight heparin preparations are as safe and effective as unfractionated heparin for the treatment of acute deep venous thrombosis. These preparations have been shown to be costeffective for thromboprophylaxis after hip replacement surgery compared with low-dose warfarin or unfractionated heparin (6). We hypothesized that despite their current higher price, low-molecular-weight heparins might also be cost-effective relative to unfractionated heparin for treating established deep venous thrombosis. If therapy with low-molecular-weight heparin resulted in fewer bleeding complications or more effectively prevented thromboembolic recurrences, the costs associated with these events would be reduced.
We developed a decision model to compare the costs and health effects of low-molecular-weight heparins and unfractionated heparin for the treatment of acute deep venous thrombosis. In our base-case analysis, we assumed that all treatment occurred in an inpatient hospital setting. To fully quantify the potential economic impact of low-molecular-weight heparin treatment, we performed a secondary analysis that allowed for the possibility of outpatient treatment with this drug.
Also a 1998 research report: Medical Advisory Panel, TEC Program, Blue Cross Blue Shield Association
Medicare Reform - the first volume in a new series sponsored by the George Bush School of Government and Public Policy at Texas A&M University - tackles the current Medicare predicament head-on, delving into the fundamental issues surrounding the reorganization of the system: whether to allocate Medicare's growing financial load to current workers in the form of higher taxes, shift the onus to future generations, or shortchange both the expectations and care of present recipients by substantially cutting benefits. This volume assembles a group of the most highly respected analysts of health issues to consider the economic forces impacting the surging health care market.
Written for the general reader and offering innovative ideas for policy revision along with critical new data on health care economics, this comprehensive volume provides a timely and thoughtful deliberation on the precarious future of Medicare.
Available as NBER working paper 6642.